We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk factors associated with mortality from vascular thromboembolic events in patients diagnosed with non-small cell lung cancer: a population-based analysis.
- Authors
He, X.-J.; Wu, Y.-Y.; Xia, M.-R.; Li, Z.-Q.; Zhao, M.; Dai, Q.-D.; Zhang, J.-P.; Xia, J.-H.; Zhang, J.-W.
- Abstract
Background: Lung cancer patients are at increased risk for vascular events possibly due to cancer induced hypercoagulation. Aim: The purpose of this study was to evaluate risk factors associated with the mortality from vascular thromboembolic events in patients diagnosed with non-small cell lung cancer (NSCLC). Design: Retrospective population-based analysis. Methods: We used Surveillance, Epidemiology and End Results Program for 2004-13 and evaluated 199 337 patients with NSCLC. Univariate and multivariate subdistribution hazard regression models were used to identify potential risk factors for mortality from vascular thromboembolic events. Stratification analysis against clinical stage was performed to determine if the severity of the disease influenced the identified associations. Results: Multivariate Cox regression analysis demonstrated that increased risk of mortality due to vascular thromboembolic events was associated with age, black race, non-adenocarcinoma histology, surgical treatment alone (all, P<0.001) and north central region of SEER registry (P=0.003). Female gender (P<0.001), Asian or Pacific Islander race (P=0.001), multiple co-existing primary cancers and late cancer stages (both, P<0.001) were associated with significantly lower risk of mortality due to vascular thromboembolic events. The significant predictors of mortality from the vascular thromboembolic event were dependent on the stages of the disease. Conclusions: Risk factors associated with mortality from the vascular thromboembolic events in NSCLC patients identified in this study can promote awareness and may help to identify groups of patients that can benefit from anti-thrombotic prophylaxis measures.
- Subjects
LUNG cancer; CANCER patients; NON-small-cell lung carcinoma; MORTALITY; THROMBOEMBOLISM
- Publication
QJM: An International Journal of Medicine, 2017, Vol 110, Issue 12, p807
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcx166